“We are not a one- or two-asset company. We’ve got a large pipeline coming out,” warns David E. Olson, founder of Delix Therapeutics.
The Boston-based startup just raised $70 million in series A financing to develop psychedelic-inspired compounds that are safe enough to take at home.
The company has already synthesized about 1,000 compounds across 8+ classes of psychedelics, with the goal of creating compounds that form synapses between brain cells without inducing hallucinations.
The researchers have found a couple of promising contenders, which are on track to be studied in Phase 1 clinical trials by the end of this year.